Mar 07, 2022 / 02:50PM GMT
Philip M. Nadeau - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
Good morning, and welcome once again to Cowen and Company's 42nd Annual Healthcare Conference. I'm Phil Nadeau, a biotech analyst here at Cowen. It's my pleasure to moderate a fireside chat with Michel Vounatsos, the CEO of Biogen. We're very happy to have him show with us today. These are incredibly busy times for Biogen.
Michel, with that, I'll hand it to you for some opening comments.
Michel Vounatsos - Biogen Inc. - CEO & Director
Thank you, Phil. Before we begin, I would like to point out that we'll be making forward-looking statements based on current expectations and beliefs. They are subject to risks and uncertainties, so I encourage you to consult the risk factors discussed in our SEC filings.
Today, I will also be discussing ADUHELM approved last year by the FDA for the treatment of Alzheimer's disease under the accelerated approval pathway. Please see the full prescribing information and patient medication guide. But let me get
Biogen Inc at Cowen Health Care Conference (Virtual) Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers